Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939759 | 0.82 | LMNA (0.36) | BRD4LMNASMN1; SMN2HTTTSHR | |
| SCHEMBL1083419 | 0.73 | HTT (0.35) | HTTALDH1A1KMT2APKM | |
| SCHEMBL25033841 | 0.69 | LOX (0.46) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL30562770 | 0.68 | EDNRB (0.50) | BRD4LMNASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL25387423 | 0.68 | EDNRB (0.50) | BRD4LMNASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL28795901 | 0.67 | TSHR (0.51) | LMNASMN1; SMN2TSHRALDH1A1MAPT | |
| SCHEMBL1751841 | 0.64 | GPR3 (0.32) | SMN1; SMN2ALDH1A1RAB9AHPGD | |
| SCHEMBL25067022 | 0.64 | NLRP3 (0.46) | LMNASMN1; SMN2TSHRALDH1A1MEN1 | |
| SCHEMBL10680402 | 0.62 | KEAP1 (0.48) | LMNATSHRALDH1A1MEN1KMT2A | |
| SCHEMBL31347243 | 0.61 | IDO1 (0.40) | LMNATSHRALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-8975439-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2015-03-10 | — | — | US | disclosed |
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2015-02-12 | — | — | US | disclosed |
| EP-2268612-B1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-20130096105-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-8362063-B2 | Arylsulfonamide based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-20120258954-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-8222424-B2 | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | MMP11, MMP10, MMP9 | BRD4 401/4885LMNA 2167/4885SMN1; SMN2 1506/4885 |
| US-20150045398-A1 | ArylSulfonamide-Based Matrix Metalloprotease Inhibitors | MMP11, MMP10, MMP9 | BRD4 401/4885LMNA 2167/4885SMN1; SMN2 1506/4885 |
| US-20120258954-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | MMP11, MMP9, MMP10 | BRD4 386/4885LMNA 2223/4885SMN1; SMN2 1567/4885 |
| US-20130096105-A1 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors | MMP11, MMP9, MMP10 | BRD4 386/4885LMNA 2223/4885SMN1; SMN2 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.